Genomic classifiers such as the Genomic Prostate Score (GPS) could help to personalize treatment for men with intermediate-risk prostate cancer (I-PCa). In this study, we aimed to evaluate the ability of the GPS to change therapeutic decision making in I-PCa. Only patients in the intermediate NCCN risk group with Gleason score 3 + 4 were considered. The primary objective was to assess the impact of the GPS on risk stratification: NCCN clinical and genomic risk versus NCCN clinical risk stratification alone. We also analyzed the predictive role of the GPS for locally advanced disease (≥pT3+) and the potential change in treatment strategy. Thirty patients were tested for their GPS between November 2018 and March 2020, with the median age being 70 (45-79). Twenty-three patients had a clinical T1 stage. Eighteen patients were classified as favorable intermediate risk (FIR) based on the NCCN criteria. The median GPS score was 39 (17-70). Among the 23 patients who underwent a radical prostatectomy, Gleason score 3 + 4 was found in 18 patients. There was a significant correlation between the GPS and the percentage of a Gleason grade 4 or higher pattern in the surgical sample: correlation coefficient r = 0.56; 95% CI = 0.2-0.8; p = 0.005. In this study, the GPS combined with NCCN clinical risk factors resulted in significant changes in risk group.
Cancers. 2023 Feb 02*** epublish ***
Yazid Belkacemi, Kamel Debbi, Gabriele Coraggio, Jérome Bendavid, Maya Nourieh, Nhu Hanh To, Mohamed Aziz Cherif, Carolina Saldana, Alexandre Ingels, Alexandre De La Taille, Gokoulakrichenane Loganadane
Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor Hospital, APHP, University of Paris Est Créteil (UPEC), IMRB, INSERM U 955, 94000 Créteil, France., Department of Pathology, Henri Mondor Hospital, University of Paris Est Créteil (UPEC), IMRB, INSERM U 955, 94000 Créteil, France., Department of Medical Oncology, Henri Mondor Hospital, University of Paris Est Créteil (UPEC), 94000 Créteil, France., Department of Urology, Henri Mondor Hospital, University of Paris Est Créteil (UPEC), 94000 Créteil, France.